Marianne P. Allen

Array ( [id] => 17734735 [patent_doc_number] => 20220220194 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => METHODS AND AGENTS FOR THE TREATMENT OF OCULAR DISEASE [patent_app_type] => utility [patent_app_number] => 17/678861 [patent_app_country] => US [patent_app_date] => 2022-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20124 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17678861 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17609894 [patent_doc_number] => 20220152173 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => Cancer Antigen Peptide [patent_app_type] => utility [patent_app_number] => 17/592381 [patent_app_country] => US [patent_app_date] => 2022-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12092 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17592381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17609893 [patent_doc_number] => 20220152172 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => Cancer Antigen Peptide [patent_app_type] => utility [patent_app_number] => 17/592375 [patent_app_country] => US [patent_app_date] => 2022-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12082 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17592375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17609895 [patent_doc_number] => 20220152174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => Cancer Antigen Peptide [patent_app_type] => utility [patent_app_number] => 17/592384 [patent_app_country] => US [patent_app_date] => 2022-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12103 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17592384 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17749622 [patent_doc_number] => 20220227826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => ENGINEERED FGF1 AND FGF2 COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/587889 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11712 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17587889 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17609302 [patent_doc_number] => 20220151581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS [patent_app_type] => utility [patent_app_number] => 17/586620 [patent_app_country] => US [patent_app_date] => 2022-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19345 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17586620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19338557 [patent_doc_number] => 12048728 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-30 [patent_title] => Highly concentrated formulations of soluble Fc receptors [patent_app_type] => utility [patent_app_number] => 17/583503 [patent_app_country] => US [patent_app_date] => 2022-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 24 [patent_no_of_words] => 11736 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17583503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595357 [patent_doc_number] => 20220144930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => Humanized Anti-VEGF Monoclonal Antibody [patent_app_type] => utility [patent_app_number] => 17/579376 [patent_app_country] => US [patent_app_date] => 2022-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12291 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17579376 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548171 [patent_doc_number] => 20220119512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => IMMUNOGLOBULIN VARIABLE DOMAINS [patent_app_type] => utility [patent_app_number] => 17/562499 [patent_app_country] => US [patent_app_date] => 2021-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74082 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17562499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17531928 [patent_doc_number] => 20220110537 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => ANTI-ANGPTL 3/8 COMPLEX ANTIBODIES AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/559808 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10470 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17559808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19120037 [patent_doc_number] => 11963998 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-23 [patent_title] => Modulation of heparin-binding epidermal growth factor activity for tympanic membrane healing [patent_app_type] => utility [patent_app_number] => 17/556193 [patent_app_country] => US [patent_app_date] => 2021-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 16 [patent_no_of_words] => 11295 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17556193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17627285 [patent_doc_number] => 20220162300 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => METHODS OF TREATING FGF21-ASSOCIATED DISORDERS [patent_app_type] => utility [patent_app_number] => 17/539335 [patent_app_country] => US [patent_app_date] => 2021-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44539 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 235 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17539335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18837719 [patent_doc_number] => 11845782 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-19 [patent_title] => Relaxin fusion polypeptides and uses thereof [patent_app_type] => utility [patent_app_number] => 17/528378 [patent_app_country] => US [patent_app_date] => 2021-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 29 [patent_no_of_words] => 13835 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17528378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20357385 [patent_doc_number] => 12473368 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-18 [patent_title] => CD25 antibodies [patent_app_type] => utility [patent_app_number] => 17/524852 [patent_app_country] => US [patent_app_date] => 2021-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 3728 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17524852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441908 [patent_doc_number] => 20220062413 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => TREATMENT OF PSYCHIATRIC CONDITIONS [patent_app_type] => utility [patent_app_number] => 17/453894 [patent_app_country] => US [patent_app_date] => 2021-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5162 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 4 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17453894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17428412 [patent_doc_number] => 20220056120 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => METHODS OF TREATING OCULAR PATHOLOGIES USING BIFUNCTIONAL MOLECULES THAT TARGET GROWTH FACTORS [patent_app_type] => utility [patent_app_number] => 17/453981 [patent_app_country] => US [patent_app_date] => 2021-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17453981 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18830868 [patent_doc_number] => 20230399393 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => METHODS TO EXTEND HEALTH-SPAN AND TREAT AGE-RELATED DISEASES [patent_app_type] => utility [patent_app_number] => 18/034672 [patent_app_country] => US [patent_app_date] => 2021-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39709 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18034672 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17830147 [patent_doc_number] => 20220267451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE [patent_app_type] => utility [patent_app_number] => 17/501430 [patent_app_country] => US [patent_app_date] => 2021-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17501430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17761525 [patent_doc_number] => 20220235137 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE [patent_app_type] => utility [patent_app_number] => 17/450872 [patent_app_country] => US [patent_app_date] => 2021-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35534 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17450872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17368336 [patent_doc_number] => 20220023388 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => FUSION PROTEINS WITH EXTENDED SERUM HALF LIFE [patent_app_type] => utility [patent_app_number] => 17/498262 [patent_app_country] => US [patent_app_date] => 2021-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26486 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17498262 [rel_patent_id] =>[rel_patent_doc_number] =>)